In an evaluation of clinical stage and rs7843546 WISP1 genotypes, patients with the TT genotype displayed a 0.34-fold lower risk of developing stage I/II gastric cancer than those with the CC genotype (OR = 0.34; 95% CI 0.14–0.84; P = 0.020) (Table 3) after adjusting for gender, age, BMI, ethnicity, smoking, and drinking. This evidence concerns the gene CCN4 and gastric cancer.